Osteogenesis Imperfecta-Congenital Joint Contractures Syndrome

Osteogenesis imperfecta–congenital? joint contractures syndrome is a very rare inherited disorder where two problems happen together from birth:

1. the bones are fragile and break easily (this is what happens in osteogenesis imperfecta), and

2. many joints are stuck in a bent or stiff position (these are congenital? joint contractures, sometimes called arthrogryposis).

Children usually show contractures at birth, then later have frequent bone fractures with minor injuries or even normal activity. Height is often short. The spine may curve (scoliosis or kyphoscoliosis). Over time, deformities can develop in the limbs and spine because of repeated fractures and the joint contractures. This association of brittle bones plus joint contractures is the hallmark of Bruck syndrome. PubMed+2Orpha.net+2

Why does it happen?

The problem comes from changes (mutations) in genes that help your body make and “mature” collagen, the main building protein in bone and connective tissues. In Bruck syndrome, the two most important genes are FKBP10 (Type 1 Bruck syndrome) and PLOD2 (Type 2 Bruck syndrome). These genes help collagen fold correctly and make strong cross-links. When they do not work, the collagen network in bone is weak, so bones break easily, and contractures can form in the womb due to poor joint movement. The condition is autosomal recessive, meaning a child is affected when both parents silently carry one changed copy of the gene. Orpha.net+3PMC+3OUP Academic+3

Other names

• Bruck syndrome

• Osteogenesis imperfecta with congenital? joint contractures

• OI with arthrogryposis

• Osteogenesis imperfecta–congenital? joint contractures syndrome (formal phrase) Wikipedia+1

Types

Type 1 (BRKS1): Usually caused by FKBP10 mutations. FKBP10 encodes FKBP65, a chaperone that helps collagen fold in the endoplasmic reticulum. When FKBP65 is missing or faulty, collagen I chains mis-fold and do not assemble and cross-link well. Bones are fragile and contractures are present from early life. PMC

Type 2 (BRKS2): Caused by PLOD2 mutations. PLOD2 encodes lysyl-hydroxylase 2, an enzyme needed to hydroxylate lysine residues that form collagen cross-links. Without proper hydroxylation, collagen cross-linking is poor and bone is weak; contractures are common. PMC

(Note: Very rarely, closely related collagen-folding genes—such as SERPINH1, which encodes the collagen chaperone HSP47—are implicated in overlapping phenotypes of recessive OI; this supports the central role of the collagen-maturation pathway.) OUP Academic

Causes

Below are causal factors and mechanisms known or strongly associated with this syndrome. Because this is a genetic condition, most “causes” are gene-level or pathway-level problems that lead to bone fragility and contractures.

1. FKBP10 mutations (Type 1) – prevent normal collagen folding (via FKBP65) → weak bone matrix. PMC

2. PLOD2 mutations (Type 2) – reduce lysyl-hydroxylation and cross-linking of collagen → poor bone strength. PMC

3. Defective collagen cross-links – fewer hydroxylysyl pyridinoline cross-links make bone brittle. PMC

4. Abnormal collagen folding – mis-folded collagen I cannot assemble into strong fibrils. OUP Academic

5. Endoplasmic reticulum (ER) stress in osteoblasts – mis-folded collagen accumulates, reducing bone formation. PMC

6. Abnormal telopeptide lysine hydroxylation – a direct effect of PLOD2 loss leading to weak cross-linking. Wikipedia

7. Autosomal recessive inheritance – two non-working copies (one from each parent) are required to cause disease. Orpha.net

8. Reduced fetal joint movement (akinesia) in utero – contributes to symmetric congenital? contractures and pterygia. PubMed

9. Generalized fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis? from early life – low bone mass increases fracture? risk. PubMed

10. Vertebral trabecular weakness? – leads to compression fractures and spinal curvature. PubMed

11. Long-bone bowing due to repeated micro-fractures – deformity plus contractures worsen mobility. PubMed

12. Progressive joint contractures – limit range of motion and can worsen deformities over time. Orpha.net

13. Pterygia (webs) across flexor surfaces – show long-standing fetal joint immobility. PubMed

14. Thoracic? cage deformity – from rib fractures and spinal curvature, affecting breathing. PubMed

15. Consanguinity (when present) increases risk – raises the chance that both parents carry the same rare recessive variant. (General genetics principle consistent with recessive disorders.) Orpha.net

16. Impaired osteoblast function – fewer functional collagen fibrils mean poor bone matrix deposition. PMC

17. Abnormal tendon?/ligament? collagen – can contribute to contracture persistence and limited joint motion. OUP Academic

18. Secondary muscle imbalance around stiff joints – fixing joints in flexion can tighten soft tissues even more over time. (Mechanistic consequence of congenital? contractures described across arthrogryposis literature.) PubMed

19. Recurrent fractures during growth – each healing episode can change bone shape and joint alignment. PubMed

20. Spinal deformity progression – multiplies mechanical stress and fracture? risk in vertebrae and ribs. PubMed

Symptoms and signs

1. Congenital? joint contractures – joints (knees, elbows, ankles, feet) are bent or stiff at birth; these may be symmetric. PubMed+1

2. Pterygia (skin webs across joints) – often across the elbows or knees; signal long-standing fetal immobility. PubMed

3. Bone fragility – bones break easily with low-energy events or normal handling. PubMed

4. Multiple fractures over childhood – often in long bones; fractures may start when the child begins to walk. PubMed

5. Short stature – due to reduced bone growth and repeated fractures/deformities. PubMed

6. Limb deformities (bowing) – especially in the femur and tibia; worsen with growth and repeated breaks. PubMed

7. Spinal curvature (scoliosis/kyphoscoliosis) – can be severe and progress, sometimes affecting breathing. PubMed

8. Chest wall deformity and rib fractures – contribute to reduced lung function in severe cases. PubMed

9. Clubfoot (talipes) and foot deformities – common because of contractures around the ankles and feet. PubMed

10. Torticollis – neck muscles tighten, holding the head to one side at birth or early life. PubMed

11. Pain? from fractures and deformities – pain? flares with breaks and may be chronic? if deformities persist. PubMed

12. Wormian bones on skull X-ray? – small extra bone islands seen in the skull, common in OI-spectrums. SpringerLink

13. Normal intelligence – cognition is typically normal unless there are unrelated complications. PubMed

14. Delayed motor milestones – due to fractures, deformities, and joint stiffness? limiting movement. PubMed

15. Thin bones (osteopenia/fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?) on imaging – the radiographic reflection of bone fragility. PubMed

Diagnostic tests

A) Physical examination

1. Birth and newborn exam for contractures – look for joints fixed in flexion/extension and for webs (pterygia). These findings help separate Bruck syndrome from “classical” OI without contractures. PubMed

2. Spine and chest exam – check for scoliosis, kyphosis, rib pain? or deformity; these suggest ongoing fragility and possible breathing issues. PubMed

3. Limb alignment and deformity check – bowing of long bones and limb length differences point to repeated fractures and poor remodeling. PubMed

4. Gait and function assessment – walking pattern, need for braces, and endurance guide therapy plans and risk of new fractures. PubMed

5. Growth monitoring – regular height/weight tracking identifies short stature and nutritional or fracture?-related growth impacts. PubMed

B) Manual/bedside functional tests

6. Range-of-motion (ROM) measurement – goniometer readings document how stiff each joint is and whether therapy is helping. PubMed

7. Contracture angle tracking over time – serial measurements show progression or improvement with splints/therapy. PubMed

8. Manual muscle testing – determines strength around stiff joints; weakness? may be secondary to pain? or disuse. PubMed

9. Breathing assessment at bedside – observation of chest movement and simple spirometry (when age-appropriate) can flag restrictive breathing from spinal/chest deformity. PubMed

C) Laboratory and pathological tests

10. Genetic testing for FKBP10 and PLOD2 – sequencing confirms Type 1 (FKBP10) or Type 2 (PLOD2) Bruck syndrome and guides family counseling. PMC+1

11. Targeted collagen-processing gene panels – may include FKBP10, PLOD2, SERPINH1, and other recessive OI genes; useful when the first test is negative but suspicion is high. OUP Academic

12. Fibroblast collagen studies (specialized) – biochemical analysis can show under-hydroxylated lysine in telopeptides and reduced cross-linking, supporting the diagnosis?. PMC

13. Bone turnover markers – alkaline phosphatase and other markers can indicate active bone remodeling but are supportive, not diagnostic. (General OI practice.) PubMed

14. Vitamin/mineral status – checking vitamin D and calcium helps optimize bone health though it does not cause Bruck syndrome. (Supportive care in OI spectrum.) PubMed

15. Histology (rarely needed) – bone biopsy? is seldom required but would show low-quality collagen matrix and osteopenia when performed. (Pathology consistent with OI variants.) PubMed

D) Electrodiagnostic tests

16. Electromyography (EMG) and nerve conduction studies – not routine for Bruck syndrome itself, but can be used when doctors need to exclude neuromuscular causes of arthrogryposis if the picture is unclear. Orpha.net

17. Evoked responses in complex cases – occasionally used to rule out central causes of fetal akinesia or other neurologic contributors when contractures are unexplained. (Problem-focused testing.) Orpha.net

E) Imaging tests

18. Plain X-rays of limbs – show osteopenia, fractures (healed and fresh), bowing, and deformities; also help plan casts, rods, or braces. PubMed

19. Spine radiographs – monitor scoliosis/kyphosis and vertebral compression; progression can drive breathing issues. PubMed

20. Skull films – may show Wormian bones, a supportive OI-spectrum sign. SpringerLink

21. DEXA (bone density scan) – quantifies low bone mass to track response to care (for example, to bisphosphonates). PubMed

22. Prenatal ultrasound? – in families at risk, can detect decreased fetal movements, limb position abnormalities, or fractures late in pregnancy. Wikipedia

23. Chest imaging – looks for rib fractures and chest wall deformities when breathing problems are suspected. PubMed

24. Targeted MRI (case-by-case) – used for complex spinal deformity planning or when soft-tissue detail is needed; not a routine test for diagnosis?. PubMed

Non-pharmacological treatments (therapies & other supports)

1. Fracture?-safe handling & transfer training.
   What: Teach families how to lift, diaper, bathe, and position without twisting long bones. Purpose: Lower fracture? risk in daily care. Mechanism: Minimizes torque/lever forces on fragile, thin cortices typical of OI. Dove Medical Press

2. Early, gentle physiotherapy.
   What: Daily range-of-motion (ROM), stretching around contractures, gradual strengthening, and posture work. Purpose: Preserve mobility, prevent further stiffness?, and improve function. Mechanism: Regular, low-load movement remodels soft tissues, modulates muscle tone, and supports motor milestones despite bone fragility. PMC

3. Aquatic therapy.
   What: Exercises in warm water. Purpose: Build strength/endurance with low fracture risk. Mechanism: Buoyancy unloads bones; water resistance provides graded strengthening and joint motion. Dove Medical Press

4. Standing program with supports.
   What: Early supported standing frames. Purpose: Hip health, alignment, and bone loading. Mechanism: Gentle weight-bearing stimulates bone formation and helps acetabular/hip development. Dove Medical Press

5. Custom orthoses & splints.
   What: AFOs, wrist splints, serial casts for contractures. Purpose: Improve alignment and function, maintain gains after stretching. Mechanism: Prolonged, low-load stretch and alignment reduce contracture progression and support gait. ResearchGate

6. Contracture management protocols.
   What: Scheduled stretching plus night splints. Purpose: Prevent fixed deformity that worsens leverage on fragile bones. Mechanism: Soft-tissue creep and remodeling lengthen shortened tissues over time. ResearchGate

7. Fall-prevention & safe mobility training.
   What: Gait training, walker/wheelchair selection, home safety. Purpose: Reduce fractures from falls. Mechanism: Improves balance and lowers impact events. Dove Medical Press

8. Spinal deformity surveillance.
   What: Regular clinical checks and radiographs. Purpose: Detect progressive kyphoscoliosis early. Mechanism: Timely bracing or referral for surgical fusion when indicated. PubMed

9. Hearing surveillance & protection.
   What: Periodic audiology; hearing protection in loud settings. Purpose: Treat early conductive/sensorineural loss. Mechanism: Hearing aids/implantable devices bypass ossicular dysfunction; prevention reduces noise-induced damage. BBS+2oif.org+2

10. Dental & craniofacial care.
    What: Early dentist involvement for enamel/dentin issues; jaw surgery planning around bisphosphonate exposure. Purpose: Maintain oral function and avoid osteonecrosis risk with IV bisphosphonates. Mechanism: Preventive dentistry and timing surgery away from active IV bisphosphonate courses. oif.org

11. Nutrition optimization (food-first).
    What: Ensure adequate protein, calcium, and vitamin D from diet. Purpose: Support mineralization and muscle. Mechanism: Vitamin D aids calcium absorption; adequate calcium/protein provide building blocks for bone matrix. Bone Health & Osteoporosis Foundation+1

12. Pain self-management (non-drug).
    What: Heat/ice, positioning, CBT-based coping, sleep hygiene. Purpose: Reduce chronic pain without medication burden. Mechanism: Gate control and central modulation of pain; better sleep lowers pain amplification. Dove Medical Press

13. School & life participation plans.
    What: Individualized education plans, sports modification. Purpose: Preserve participation and mental health. Mechanism: Tailored physical demands lower injury risk while keeping activity levels up. Dove Medical Press

14. Bone density & growth monitoring.
    What: Periodic DEXA; growth and nutrition review. Purpose: Track response to therapy and adjust supports. Mechanism: Objective trends in BMD and growth guide rehab and surgical timing. PubMed

15. Respiratory care in severe deformity.
    What: Breathing exercises and pulmonary follow-up if chest deformity. Purpose: Maintain lung function. Mechanism: Improves ventilation mechanics limited by rib/spine deformity. Dove Medical Press

16. Home modifications.
    What: Ramps, rails, non-slip flooring, bathroom aids. Purpose: Prevent falls and overload. Mechanism: Environmental control reduces high-risk maneuvers. Dove Medical Press

17. Contracture-relief devices.
    What: Dynamic splints/serial casting for elbows/knees/ankles. Purpose: Improve ROM without high-force stretching. Mechanism: Gentle, continuous stretch encourages tissue remodeling safely. ResearchGate

18. Assistive tech & mobility aids.
    What: Lightweight chairs, telescoping crutches, custom seating. Purpose: Promote independence with protection. Mechanism: Distributes loads, reduces fatigue and stumble risk. Dove Medical Press

19. Psychological and family support.
    What: Counseling and peer networks. Purpose: Address anxiety/depression and caregiver strain. Mechanism: Skills training improves adherence and coping with chronic care. Dove Medical Press

20. Multidisciplinary coordination.
    What: Regular team clinics (orthopedics, rehab, audiology, dentistry, genetics). Purpose: Seamless care across life stages. Mechanism: Reduces gaps, optimizes timing of bracing, therapies, and surgeries. PMC

Drug treatments

Important safety note: No medicine is FDA-approved specifically for Bruck syndrome. Most bone-active drugs are used off-label based on OI experience. Pediatric use is restricted for several agents—details below. Always treat under a specialist team.

1. Pamidronate (IV bisphosphonate).
   Class: Bisphosphonate (osteoclast inhibitor). Typical pediatric cyclic dosing (specialist protocols vary): e.g., 0.5–1 mg/kg/day over 3 consecutive days every 3–4 months; slow infusion. Purpose: Increase vertebral size/BMD, reduce bone pain and fracture rate in moderate–severe OI. Mechanism: Binds bone mineral, inhibits osteoclast resorption, allowing secondary bone fill-in. Side effects: Fever, hypocalcemia, bone pain; renal monitoring needed. FDA labeling details formulation/safety (pamidronate not specifically approved for pediatric OI). FDA Access Data+1

2. Zoledronic acid (IV).
   Class: Potent bisphosphonate. Dosing: Pediatric OI studies used ~0.025–0.05 mg/kg IV at intervals; not indicated for children—use only in expert centers. Purpose: Improve BMD and vertebral reshaping; long dosing interval is convenient. Mechanism: Strong farnesyl pyrophosphate synthase inhibition in osteoclasts. Side effects: Acute-phase reactions, hypocalcemia; long skeletal retention; pediatric labels caution use. FDA Access Data+2FDA Access Data+2

3. Alendronate (oral).
   Class: Bisphosphonate. Dosing: Adults 70 mg weekly (label); pediatric OI use is off-label. Purpose: Maintenance therapy in selected ambulant patients. Mechanism: Inhibits osteoclasts to reduce turnover. Side effects: Esophagitis (upright dosing), rare atypical femur fracture/ONJ with long-term use. FDA Access Data+1

4. Risedronate (oral).
   Class: Bisphosphonate. Dosing: 35 mg weekly (adults, label). Purpose: Alternative oral option where IV access is difficult. Mechanism: Osteoclast inhibition. Side effects: GI upset; similar class cautions. FDA Access Data

5. Ibandronate (IV/PO, adults).
   Class: Bisphosphonate. Dosing (adult label): 150 mg monthly PO or 3 mg IV every 3 months. Purpose: Adult OI/low-turnover bone off-label when others unsuitable. Mechanism/side effects: As class; caution renal and hypocalcemia risks. (adult FDA label accessible; not essential in pediatric Bruck—omitted for brevity)

6. Teriparatide (PTH 1-34, adults only).
   Class: Anabolic osteoporotic agent. Dosing: 20 µg SC daily (adult label). Purpose: Considered in selected adults with milder OI to stimulate new bone formation (not for children, not studied in Bruck; specialist decision only). Mechanism: Intermittent PTH stimulates osteoblasts. Side effects/warnings: Not established in pediatrics; avoid with open epiphyses; label changes removed the boxed warning but pediatric use remains contraindicated. FDA Access Data+2FDA Access Data+2

7. Denosumab (adults; avoid in pediatric OI).
   Class: RANKL inhibitor (anti-resorptive). Dosing (adult osteoporosis): 60 mg SC every 6 months. Purpose: Alternative anti-resorptive in adults when bisphosphonates are unsuitable. Mechanism: Blocks osteoclast formation. Critical pediatric caution: FDA labels warn of severe/life-threatening hypercalcemia reported in pediatric OI; not approved for children. Other risks: Hypocalcemia, ONJ, atypical fractures. FDA Access Data+2FDA Access Data+2

8. Calcitonin-salmon (intranasal/injectable).
   Class: Anti-resorptive peptide. Dosing (adult label): Nasal 200 IU daily. Purpose: Short-term vertebral fracture pain control when other options fail (modest effect on BMD). Mechanism: Reduces osteoclast activity; analgesic effect in acute vertebral fractures. Side effects: Rhinitis, signal for increased malignancy risk in meta-analysis; usually not first-line long-term. FDA Access Data+1

9. Calcium (as a medicine when deficient).
   Class: Mineral supplement/medical therapy. Dosing: Age-appropriate RDA; correct deficiency. Purpose: Ensure substrate for mineralization and prevent infusion-related hypocalcemia with bisphosphonates. Mechanism: Provides ionic calcium for hydroxyapatite. Side effects: Constipation, kidney stones with excess. Office of Dietary Supplements

10. Vitamin D3 (cholecalciferol).
    Class: Vitamin/hormone. Dosing: Age-appropriate RDA; treat deficiency per guidelines. Purpose: Enable calcium absorption; prevent osteomalacia complicating OI. Mechanism: Upregulates intestinal calcium transport and bone mineralization. Side effects: Hypercalcemia with overdose. Office of Dietary Supplements

11. Acetaminophen (paracetamol).
    Class: Analgesic. Dosing: Weight-based pediatric dosing; avoid overdose. Purpose: First-line pain control for fractures/post-op. Mechanism: Central analgesia (COX modulation). Side effects: Hepatotoxicity in overdose (follow label). (general FDA label exists; pain control standard)

12. Ibuprofen / NSAIDs.
    Class: NSAID analgesic. Dosing: Weight-based pediatric dosing. Purpose: Pain and inflammation; often adjunct to acetaminophen. Mechanism: COX inhibition reduces prostaglandins. Side effects: Gastritis, renal risk; avoid dehydration.

13. Peri-operative antibiotics (as indicated).
    Class: Antibacterials. Purpose: Reduce infection risk in rodding/spinal fusion. Mechanism: Standard surgical prophylaxis protocols. Side effects: Class-specific.

14. Bisphosphonate pre-/post-op timing (protocol adjustment).
    What: Temporarily avoid IV bisphosphonates around jaw surgery; coordinate with dentists/surgeons. Why: Reduce osteonecrosis-of-jaw risk and support bone healing. oif.org

15. Topical anesthetics & regional blocks.
    Purpose: Pain control for casting/line placement and surgery with less systemic drug use. Mechanism: Local sodium-channel blockade. Side effects: Rare systemic toxicity if overdosed.

16. Antispasticity options (selected cases).
    What: Baclofen or botulinum toxin if spasticity compounds contractures (rare; specialist judgment). Mechanism: Muscle tone reduction to aid stretching. Risks: Sedation/weakness with baclofen; localized weakness with BoNT.

17. Anti-resorptive cycling strategies.
    What: Titrate IV bisphosphonate cycles to response (BMD, pain, fractures), usually most benefit in first 2–4 years. Why: Avoid over-suppression of turnover. Frontiers+1

18. Peri-infusion calcium/vitamin D.
    What: Ensure repletion before/after IV bisphosphonate. Why: Lower hypocalcemia risk. Mechanism: Offsets acute resorption block. Office of Dietary Supplements+1

19. Post-operative thromboprophylaxis (as indicated).
    What: Doses per weight/age when immobility is prolonged after spinal/long-bone surgery. Why: Reduce VTE risk. Mechanism: Anticoagulation counters immobilization risk.

20. Avoid/limit certain agents in children with OI.
    What: Denosumab (risk of severe hypercalcemia after stopping) and teriparatide (not for open epiphyses) generally avoided in pediatrics. Why: FDA safety warnings; not approved for children. FDA Access Data+2FDA Access Data+2

Dietary molecular supplements

(Food-first is best; supplements are for medically confirmed gaps and should be supervised.)

1. Calcium (diet prioritized; supplement if needed).
   Dose: Age-appropriate RDA; adjust to total daily intake from food. Function: Mineral for bone hardness. Mechanism: Builds hydroxyapatite; deficiency weakens bones. Office of Dietary Supplements

2. Vitamin D3.
   Dose: RDA for age; replete deficiency per clinician. Function: Enables calcium absorption and bone remodeling. Mechanism: Upregulates calcium/phosphate handling. Office of Dietary Supplements

3. Vitamin K2 (MK-7).
   Dose: Typical supplement 45–180 µg/day in adults (specialist guidance in children). Function: Activates osteocalcin (γ-carboxylation) and may support bone strength. Mechanism: Shifts calcium toward bone; may modulate RANKL/OPG signaling. Evidence is strongest in postmenopausal osteoporosis; pediatric OI data are limited. PMC+1

4. Magnesium.
   Dose: RDA-based; avoid excess in renal impairment. Function: Matrix mineral and cofactor for vitamin D metabolism. Mechanism: Influences PTH and bone quality.

5. Zinc.
   Dose: RDA-based. Function: Collagen synthesis and alkaline phosphatase activity. Mechanism: Cofactor for enzymes in matrix formation.

6. Silicon (e.g., orthosilicic acid).
   Dose: No established RDA; studied intakes ~10–40 mg/day in adults. Function: Supports collagen cross-linking and bone matrix quality. Mechanism: May inhibit osteoclasts and aid mineralization; human data suggest positive BMD associations. PMC+2PubMed+2

7. Boron.
   Dose: Avoid >20 mg/day (UL in adults); food-first preferred. Function: May influence calcium metabolism and steroid hormones affecting bone. Mechanism: Modulates osteoblast/osteoclast activity; evidence still evolving. Office of Dietary Supplements+1

8. Vitamin C (ascorbate).
   Dose: RDA-based. Function: Required for collagen hydroxylation. Mechanism: Cofactor for prolyl/lysyl hydroxylases; deficiency impairs collagen stability.

9. Protein (adequate, not excessive).
   Dose: Age-based needs; consider 1.0–1.5 g/kg/day in rehab phases per clinician/dietitian. Function: Provides amino acids for matrix proteins. Mechanism: Supports muscle and bone anabolism.

10. Omega-3 fatty acids.
    Dose: Food-first (fatty fish); supplements individualized. Function: Anti-inflammatory support for musculoskeletal health. Mechanism: Modulates cytokines that influence bone turnover; human fracture data mixed.

Note: Recent USPSTF draft recommendations found no fracture-prevention benefit from routine vitamin D ± calcium in average-risk community-dwelling older adults; this does not apply to patients with diagnosed bone disease or deficiency. Use supplements to correct confirmed deficits and as part of a broader plan. USPSTF

Drugs sometimes discussed as “immunity boosters / regenerative / stem-cell related”

(These are not routine therapies for Bruck syndrome; included here because you asked. Use only in clinical trials or specialist contexts.)

1. Teriparatide (PTH 1-34, anabolic; adults only).
   Dose: 20 µg SC daily. Function: Stimulates bone formation. Mechanism: Activates osteoblasts; not for pediatric patients with open epiphyses. FDA Access Data

2. Denosumab (RANKL inhibitor; adults).
   Dose: 60 mg SC q6 months. Function: Potent anti-resorptive. Mechanism: Blocks osteoclastogenesis; avoid in pediatric OI due to severe hypercalcemia risk on withdrawal. FDA Access Data

3. Recombinant human growth hormone (rhGH).
   Dose: Pediatric endocrine specialist only. Function: May aid growth/lean mass in selected short children without closed epiphyses; OI evidence mixed. Mechanism: IGF-1–mediated bone/muscle effects.

4. Experimental cell-based therapies (e.g., mesenchymal stem cells).
   Function: Theoretical collagen/cell support. Mechanism: Donor cells may contribute to osteoblast pools; evidence remains investigational.

5. BMP-related agents (surgical bone healing adjuncts).
   Function: Enhance local bone healing around osteotomies/fusions (surgeon-specific). Mechanism: Osteoinductive signaling; not a systemic OI therapy.

6. Nutrient-hormonal support (vitamin D/calcium/protein) around bone-active cycles.
   Function: Support remodeling with fewer adverse effects. Mechanism: Corrects deficiency; reduces hypocalcemia during anti-resorptive therapy. Office of Dietary Supplements+1

Surgeries (procedures & why done)

1. Intramedullary rodding of long bones (e.g., Fassier–Duval telescopic rods).
   Procedure: Osteotomies to straighten a bowed bone, then insert a rod that “grows” with the child. Why: Reduce fractures, straighten limbs, improve walking and self-care. PMC+1

2. Spinal fusion/instrumentation for progressive scoliosis/kyphosis.
   Procedure: Correct and stabilize the curve with rods/screws; fusion of segments. Why: Prevent cardiopulmonary compromise, improve sitting balance and pain. PubMed

3. Soft-tissue releases (e.g., Achilles or knee flexion contracture release).
   Procedure: Lengthen tight tendons/capsules. Why: Improve ROM and bracing tolerance, reduce lever-arm stress that predisposes to fractures. PubMed

4. Revision of migrated/failed rods.
   Procedure: Replace or reposition telescopic implants that no longer function or have migrated. Why: Restore alignment and durability as the child grows. MDPI+1

5. Ear/hearing surgery in selected cases (e.g., stapes surgery) or implantable hearing devices.
   Procedure: Stapedotomy/stapedectomy, cochlear or bone-anchored implants. Why: Treat conductive or mixed hearing loss that limits communication; success rates vary and surgery is technically demanding in OI. Nature

Preventions (practical, everyday)

1. Learn safe handling from your team to avoid torsion on long bones. Dove Medical Press

2. Keep up with physiotherapy and home stretching to slow contractures. PMC

3. Use orthoses and mobility aids correctly to reduce falls. ResearchGate

4. Maintain adequate dietary calcium and vitamin D (supplement only if deficient). Bone Health & Osteoporosis Foundation+1

5. Child-proof and modify the home to minimize impact and slips. Dove Medical Press

6. Annual/regular audiology, with hearing protection in loud settings. oif.org

7. Dental prevention and plan any jaw surgery around IV bisphosphonate cycles. oif.org

8. Monitor spine for progressive curves; treat early. PubMed

9. Ensure adequate protein and overall nutrition to support growth.

10. Avoid unsupervised use of powerful bone drugs in children (e.g., denosumab, teriparatide). FDA Access Data+1

When to see doctors urgently or promptly

• After any fall or sudden limb pain/swelling (possible fracture). Early immobilization reduces complications. Dove Medical Press

• If pain persists or function worsens despite therapy (may signal deformity progression or implant issues). saoj.org.za

• If breathing becomes harder or posture changes rapidly (possible spinal curve progression). PubMed

• If new hearing problems (tinnitus, muffled sound) appear. Early audiology helps. BBS

• Before dental or orthopedic surgery to coordinate bisphosphonate timing. oif.org

• If starting/stopping powerful bone drugs (e.g., denosumab) due to rebound risks. U.S. Food and Drug Administration

Foods to emphasize & 10 to limit/avoid

Emphasize (what to eat):

1. Dairy or fortified alternatives (milk, yogurt) for calcium. Bone Health & Osteoporosis Foundation

2. Small bony fish (sardines) for calcium + vitamin D. Bone Health & Osteoporosis Foundation

3. Fatty fish (salmon, mackerel) for vitamin D and omega-3s.

4. Leafy greens (kale, bok choy) for calcium and K. Bone Health & Osteoporosis Foundation

5. Eggs and fortified cereals (vitamin D).

6. Beans, lentils, tofu (protein + minerals).

7. Nuts/seeds (almonds, sesame) for calcium/magnesium.

8. Citrus/berries/peppers (vitamin C for collagen).

9. Whole grains (magnesium, trace minerals).

10. Adequate plain water (hydration supports rehab performance).

Limit/avoid (why):

1. Sugary drinks (empty calories displace nutrients).

2. Excess salt (higher urinary calcium losses).

3. Excess caffeine/energy drinks (may increase calcium loss; moderation).

4. Ultra-processed snacks (low nutrient density).

5. Very low-protein diets (poor matrix building).

6. Excess vitamin A supplements (bone effects at high doses).

7. Alcohol (adolescents/adults)—impairs bone and balance.

8. Fad elimination diets without medical oversight.

9. Unverified “bone boosters” online (safety unknown).

10. High-dose supplements without testing/monitoring (kidney stones, toxicity). USPSTF

Frequently asked questions

1. Is Bruck syndrome the same as OI?
   It’s a rare OI variant where brittle bones occur with congenital contractures, often from FKBP10/PLOD2 variants. Orpha.net+1

2. Can therapy make bones normal?
   No, but fracture-safe handling, PT, bracing, and surgery together can cut fractures and improve function. Dove Medical Press+1

3. Do bisphosphonates cure the disease?
   They don’t cure; they increase BMD and often reduce pain/fractures—greatest benefit in the first 2–4 years—then dosing is individualized. Frontiers

4. Are IV bisphosphonates safe for kids?
   They’re widely used in specialized centers; monitor for fever, hypocalcemia, renal effects; coordinate around dental surgery. FDA Access Data+1

5. Should children receive denosumab?
   Generally no—FDA labels warn of severe hypercalcemia in pediatric OI; it’s not approved in children. FDA Access Data

6. What about teriparatide?
   Adults only in selected cases; not for children with open growth plates. FDA Access Data

7. Do supplements replace medicines?
   No. They correct deficiencies and support therapy; they don’t replace fracture prevention, bracing, or surgery. Office of Dietary Supplements+1

8. How often should hearing be checked?
   At baseline, then periodically (many programs every 1–3 years) and earlier if symptoms appear. Use hearing protection. sciencedirect.com+1

9. When is rodding surgery considered?
   Recurrent fractures, deformity that hinders function, or rods outgrown/failing—after careful team assessment. PMC

10. Will spinal fusion affect growth?
    Fusion stops growth at fused segments, but can protect lung function and sitting balance in progressive curves. PubMed

11. Is aquatic therapy safe?
    Yes—buoyancy reduces stress while building strength and ROM under therapist guidance. Dove Medical Press

12. Can braces or splints worsen stiffness?
    Used correctly, they maintain ROM gained by stretching; protocols adjust to avoid over-immobilization. ResearchGate

13. Do vitamin D and calcium prevent fractures by themselves?
    Not reliably in average-risk adults; in OI they are supportive when deficient, not stand-alone cure. USPSTF

14. Are there gene-targeted treatments yet?
    Not in routine care. Research is ongoing; current care focuses on mechanical support + bone remodeling strategies. PMC

15. What’s the long-term outlook?
    With modern therapy (safe handling, PT, rodding, selective bone medicines, hearing/dental care), many children achieve better mobility and participation than in the past, though lifelong follow-up is standard. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 03, 2025.